Академический Документы
Профессиональный Документы
Культура Документы
Open Access Macedonian Journal of Medical Sciences. 2015 Sep 15; 3(3):521-527.
http://dx.doi.org/10.3889/oamjms.2015.087
eISSN: 1857-9655
Review Article
1* 2
Lidija Veterovska Miljkovik , Vera Spiroska
1 2
Institute for Gerontology “13. November”, Skopje, Republic of Macedonia; University Clinic of Cardiology, Faculty of
Medicine, Ss Cyril and Methodius University of Skopje, Skopje, Republic of Macedonia
Abstract
Citation: Veterovska Miljkovik L, Spiroska V. Heart
Failure with Preserved Ejection Fraction – Concept,
Heart failure (HF) with preserved left ventricular (LV) ejection fraction (HFpEF) occurs in 40 to 60%
Pathophysiology, Diagnosis and Challenges for of the patients with HF, with a prognosis which is similar to HF with reduced ejection fraction
Treatment. OA Maced J Med Sci. 2015 Sep 15; 3(3):521-
527. http://dx.doi.org/10.3889/oamjms.2015.087 (HFrEF). HFpEF pathophysiology is different from that of HFrEF, and has been characterized with
Key words: hearth failure; diastole; preserved ejection diastolic dysfunction. Diastolic dysfunction has been defined with elevated left ventricular stiffness,
fraction; echocardiography; old people. prolonged iso-volumetric LV relaxation, slow LV filing and elevated LV end-diastolic pressure.
*
Correspondence: Lidija Veterovska Miljkovik, MD.
Institute for Gerontology “13. November”, Skopje,
Arterial hypertension occurs in majority cases with HFpEF worldwide. Patients are mostly older and
Republic of Macedonia. E-mail: obese. Diabetes mellitus and atrial fibrillation appear proportionally in a high frequency of patients
lidijaveterovskamiljkovic@yahoo.com
with HFpEF. The HFpEF diagnosis is based on existence of symptoms and signs of heart failure,
Received: 01-jun-2015; Revised: 10-Jun-2015;
Accepted: 22-Jun-2015; Online first: 28-Jul-2015 normal or approximately normal ejection and diagnosing of LV diastolic dysfunction by means of
Copyright: © 2015 Lidija Veterovska Miljkovik, Vera heart catheterization or Doppler echocardiography and/or elevated concentration of plasma
Spiroska. This is an open access article distributed under
the terms of the Creative Commons Attribution License,
natriuretic peptide. The present recommendations for HFpEF treatment include blood pressure
which permits unrestricted use, distribution, and control, heart chamber frequency control when atrial fibrillation exists, in some situations even
reproduction in any medium, provided the original author
and source are credited. coronary revascularization and an attempt for sinus rhythm reestablishment. Up to now, it is
Competing Interests: The authors have declared that no considered that no medication or a group of medications improve the survival of HFpEF patients.
competing interests exist. Due to these causes and the bad prognosis of the disorder, rigorous control is recommended of the
previously mentioned precipitating factors for this disorder. This paper presents a universal review
of the most important parameters which determine this disorder.
and prognosis impact more cardiovascular Prevalence of diastolic heart failure is higher
disturbances [1]. It is expected that in the next decade in people older than 75 years. The mortality rate in
HFpEF will become a dominant cause for heart failure patients with diastolic heart failure ranges between 5
worldwide, and due to that it becomes a provocative and 8%, compared to the patients with systolic heart
and important healthy problem for which, still, no failure, in whom it ranges between 10 and 15%.
treatment has been established, which will improve Morbidity, including the frequency of hospitalizations,
the prognosis of this disorder [1]. has been approximately equal in these two groups of
patients [8].
Up to now, it is considered that no medication
or a group of medications improve the survival of
HFpEF patients. Due to these causes and the bad
prognosis of the disorder, rigorous control is
recommended of the previously mentioned
precipitating factors for this disorder. This paper
presents a universal review of the most important
parameters which determine this disorder.
522 http://www.mjms.mk/
http://www.id-press.eu/mjms/
Veterovska Miljkovik & Spiroska. Heart Failure with Preserved Ejection Fraction
_______________________________________________________________________________________________________________________________
dysfunction, which is manifested with prolonged time correspond with the pressure changes. If, small
duration of the left chamber relaxation and stress volume variations, cause significant changes in
intolerance [9]. It is proved, in trials, that aging, on its diastolic pressure for longer period, there is a
own, leads to diastolic dysfunction, oxidative stress tendency for the patients to develop venous
and protein modification [9]. Left ventricular filing as a congestion and diastolic heart failure [12].
dynamic phase of diastole has been disturbed most
When the left ventricular function has been
frequently due to myocardial fibrosis or hypertrophy
disturbed, the heart “output” is decreased concerning
[11].
the incomplete filing of the LC in diastole, and as a
Myocardial fibrosis has been caused by compensatory mechanism elevates the LC end-
humoral factors such as various types of cytokines, diastolic pressure, consequently the left atrial
“growth factors” and hormones. In hypertensive pressure also elevates and as a final result a direct
HFpEF, the oxidative stress increases the angiotensin pulmonary congestion.
II secretion from the blood vessels walls, due to
In the recent years, the new studies changed
elevated blood pressure. This results in fibroblast
the concept, which traditionally was associated with
activation and increased protein-1 production of the
development of heart failure with preserved systolic
transforming “growth factor” from macrophages and
function [13]. These studies showed that the heart
activation of monocyte haemotaxic protein-1. This
failure with preserved systolic function was a separate
results in perivascular inflammation, which is
entity, which pathophysiology was complex and not to
considered as a cause for reactive myocardial fibrosis
the end elucidated, and which needed different clinical
[11].
approach from that which was applied for heart failure
with impaired ejection fraction. Diastolic dysfunction
has a central role in pathophysiology of heart failure
with preserved ejection fraction, although it, on its
own, could not be a cause to develop a clinical picture
of heart failure. In that sense, it is important to
emphasize that there is a great number of patients
who have diastolic dysfunction, are asymptomatic and
do not have signs for heart failure, even more that the
prevalence of diastolic dysfunction surpasses 25% of
the general population [13]. Among the "extra hearth"
disorders which are pointed in pathophysiology of the
heart failure with preserved systolic function are:
endothelial dysfunction, changes of the blood vessel
walls and reduced vasodilatation reserve [6].
Figure 3: Grades of diastolic dysfunction by means of pulsed wave mitral Doppler and tissue Doppler mitral annular measurement [17]
concentration. Cardiac magnetic resonance imaging corresponds to A-wave. The E/A ratio is considered to
(CMRI) is a new modality for diagnosing of diastolic be a primary indicator for diastole. If disturbance of
dysfunction [14]. ventricular relaxation occurs, it comes to reduction of
transvalvular gradient at the beginning of diastole,
Echocardiography is the most important
which consequently leads to reduction of the E-wave.
diagnostic method in patients with heart failure, as to
Due to this, the atrial discharge disturbs, as a result to
the fact that the physical exam, the electrocardiogram
that the atrial contraction should be stronger, which is
and the X-ray do not give sufficient information, to
manifested with elevation of the A-wave. E/A ratio
distinguish the systolic from diastolic heart failure [12].
changes which is characteristically for the first grade
Establishment of diastolic function of the left of diastolic dysfunction. If the left atrial pressure is
chamber is an integral routine element of the elevated for longer time, it causes symptoms of
echocardiographic evaluation of each patient. intolerance for physical effort (second grade of
diastolic dysfunction). In patients in whom the LV
Four grades of diastolic dysfunction are
diastolic pressure is so elevated, in order to restrict
determined by echocardiography: First grade of
the transvalvular flow during the atrial contraction and
diastolic dysfunction or disturbed relaxation (Е/А <
constantly elevated left atrial pressure, it is called the
0.8, DT > 200 ms, IVRT > 100 ms, S > D, е' < 8 cm/s, third or restrictive type of diastolic dysfunction which is
Ar-A < 30m sec). Second grade of diastolic manifested with harder intolerance for physical effort
dysfunction or pseudo-normalization (E/A 0.8-1.5, DT-
[4, 6].
normal, S/D < 1, Ar-A > 30cm/s, E/е is increasing to 9-
12, can be bigger). Third to fourth grade of diastolic The analysis of the flow through pulmonary
dysfunction or restrictive ventricular filing EA >2, IVRI veins by means of pulsed Doppler, is an indirect
<60 ms, DT <160 ms reduced or none, septal Е/ е' indicator for atrial pressure, which, in absence of
>15). In this grade, LC relaxation has been seriously mitral valvular change, corresponds to LV diastolic
disturbed while significantly increased the ventricular pressure [4]. Pulsed Doppler of pulmonary flow
pressure. measures the “peak systolic“ (S), “peak anterograde
diastolic” (D) and “peak atrial reversal“ (Ar) velocities
The flow through mitral valve in diastole
in apical four-cavity space, which is a good indicator
depends on transvalvular pressure gradient [4]. In
of diastolic dysfunction [17, 18].
normal conditions, this gradient is maximal
immediately after the mitral valve opening, when Other important indicators of diastolic
corresponds with E-wave. Then, a period of reduced dysfunction are tissue Doppler mitral annular
transvalvular gradient follows, which denotes a null measurement as well as the left atrial (LA) volume
flow (diastasis). Atrial contraction, which follows after measurement and LA functional discharge index [12].
that, causes a new gradient and flow, which The tissue Doppler (TDI) measures the mitral annular
_______________________________________________________________________________________________________________________________
524 http://www.mjms.mk/
http://www.id-press.eu/mjms/
Veterovska Miljkovik & Spiroska. Heart Failure with Preserved Ejection Fraction
_______________________________________________________________________________________________________________________________
velocities including the systolic, early diastolic (е') and heart failure in older population [9].
late diastolic (a) annular velocity. Patients with (е')
In the past years, several studies pointed the
septal < 8 cm/s have disturbed left ventricular
significant connection of some biomarkers by
relaxation. The Association of Echocardiography in
appearance of the heart failure subtypes [11]. In line
scope of the European Society of Cardiology
with them, the plasma B-natriuretic peptide
regulated that the ratio E/е' < 8 has been
concentration in HFpEF was lower than in the patients
characterized with normal left ventricular filing, while
with HFrEF [11]. Highly sensitive troponin T was
the E/е' > 15 denotes elevated left ventricular
significantly associated with development of HFrEF.
pressure during filing [12, 18].
On the other hand, the growing factor (GDF 15),
cystatin C, and the urinary albumin excretion were
significantly associated with development of HFpE [7].
Treatment modalities
pressure and bring to regression the LC hypertrophy preserved ejection fraction was better than that of the
[5]. In addition, there are not sufficient trials with these patients with reduced ejection fraction. The facts
medications, which will prove, with certainty, their worry that the survival of the patients with heart failure
benefits on mortality reduction of the HFpEF patients. with preserved ejection fraction was not better in the
last decades, opposite to longer survival of the
Aldosterone is found to play a role in
patients with systolic heart failure.
occurrence of cardiac fibrosis [16]. It is found that the
aldosterone level showed a rise with advance of the In patients with heart failure, diastolic
age [16]. Higher aldosterone concentrations were dysfunction is a bigger prognostic indicator for
found in patients with diastolic heart failure, compared mortality than the ejection fraction [8, 27].
to the control group, but not so high, as in the patients
There are controversies in literature
with systolic heart failure. Also, aldosterone was found
concerning the terminology, such as “Diastolic heart
to increase the LV mass in hypertensive patients
failure” or Heart failure with preserved ejection
independently than the plasma renin activity [16].
fraction”. The authors who preferred the former term
Accordingly, blockade of aldosterone could improve
probably did not take into account the fact that some
the cardiac fibrosis and LV performances [16].
systolic disturbances almost always were present in
Efficacy and safety of the long term aldosterone
the patients with diastolic heart failure which were
receptor blockade in HFpEF patients was investigated
frequently proved by echocardiography, which spoke
in Aldo-DHF randomized, multicentric, prospective
that this was a complex phenomenon that should be
study. By this treatment, the study showed that the left
viewed as one entity [11].
ventricular diastolic function and the left ventricular re-
modeling improved, but, however, the intolerance for Diastolic and systolic heart failure should not
physical effort, the patients’ symptoms and the be considered as completely separate entities,
patients’ quality of life did not. In a study of 245 diastolic function is disturbed even in systolic heart
patients having heart failure with ejection fraction failure and is considered that it stresses even more
>40%, treated with Carvedilol in standard doses within the intolerance to physical effort and determines the
a period of 3.2 years, compared to the control group prognosis.
which was not treated with Carvedilol, the prognosis
did not improve in HFpEF patients [24].
In Randomized Aldactone Evaluation Study,
correlation was found between the clinical benefit from
the spironolactone use on serum markers for cardiac
fibrosis, but other studies were lacking, which, with
certainty, would determine the place of aldosterone
inhibitors in the treatment of HFpEF patients [16]. This
indicated that the data-base of the total of 53878
patients examined in 30 published studies (18
randomized controlled and 12 observed studies),
showed that combined therapy could improve the
symptoms of the HFpEF patients, but not the mortality
rate [10, 25]. New modalities of HFpEF treatment in
future could depend on profound knowledge for
pathophysiology of diastolic heart failure. Figure 5: Systolic and diastolic heart failure-two phenotypes with
different pathophysiology that are together linked [11]
Some new medications promise to be used in
the treatment of HFpEF in future. Phospodiesterase 5
inhibitors are considered to reduce LV and arterial On the other hand, systolic contractile
stiffness, to improve the endothelial function and disturbances measured by tissue Doppler are also
reduce the pulmonary vascular resistance /RELAX- detected in diastolic heart failure. Accordingly, it
study/ [10, 26]. Alagebrium chloride is a new agent comes out that the heart failure is the only entity with
which, in experimental research in animals, was found two phenotypes, which complement to each other
to improve the ventricular and vascular compliance, to [11].
reduce the blood pressure and vascular stiffness [20,
27].
526 http://www.mjms.mk/
http://www.id-press.eu/mjms/
Veterovska Miljkovik & Spiroska. Heart Failure with Preserved Ejection Fraction
_______________________________________________________________________________________________________________________________
van Gilst WH. Incidence and epidemiology of new onset heart 18. Todaro MC, Choudhuri I, Belohlavek M, Jahangir A, Carerj S,
failure with preserved vs. reduced ejection fraction in a Oreto L, Khandheria BK. New echocardiographic techniques
community-based cohort: 11-year follow-up of PREVEND. Eur for evaluation of left atrial mechanics. Eur Heart J Cardiovasc
Heart J. 2013;34(19):1424-31. Imaging. 2012;13(12):973-84.
3. Asrar Ul, Haq M, Mutha V, Rudd N, Hare DL, Wong C. Heart 19. Edelmann F, Wachter R, Schmidt AG, Kraigher-Krainer E,
failure with preserved ejection fraction - unwinding the Colantonio C, Kamke W, Duvinage A, Stahrenberg R,
diagnosis mystique. Am J Cardiovasc Dis. 2014;4(3):100-13. Durstewitz K, Löffler M, Düngen HD, Tschöpe C, Herrmann-
Lingen C, Halle M, Hasenfuss G, Gelbrich G, Pieske B; Aldo-
4. Roscani MG, Matsubara LS, Matsubara BB. Heart failure with DHF Investigators. Effect of spironolactone on diastolic
normal ejection fraction. Arq Bras Cardiol. 2010;94(5):652-60, function and exercise capacity in patients with heart failure
694-702. with preserved ejection fraction: the Aldo-DHF randomized
5. Li SY, Du M, Dolence EK, Fang CX, Mayer GE, Ceylan-Isik controlled trial. JAMA. 2013;309(8):781-91.
AF, LaCour KH, Yang X, Wilbert CJ, Sreejayan N, Ren J. 20. Dénes M, Kiss I, Lengyel M. Assessment of diastolic
Aging induces cardiac diastolic dysfunction, oxidative stress, dysfunction in elderly hypertensive patients using integrated
accumulation of advanced glycation endproducts and protein Doppler echocardiography. Blood Press. 2009;18(3):135-41.
modification. Aging Cell. 2005;4(2):57-64.
21. Russo C, Jin Z, Homma S, Rundek T, Elkind MS, Sacco RL,
6. Phan TT, Shivu GN, Abozguia K, Sanderson JE, Frenneaux Di Tullio MR. Left atrial minimum volume and reservoir function
M. The pathophysiology of heart failure with preserved ejection as correlates of left ventricular diastolic function: impact of left
fraction: from molecular mechanisms to exercise ventricular systolic function. Heart. 2012;98(10):813-20.
haemodynamics. Int J Cardiol. 2012;158(3):337-43.
22. Velagaleti RS, Gona P, Pencina MJ, Aragam J, Wang TJ, Levy
7. Sachihiko N, Kengo S, Yukiko I, Hisanobu A, Masaaki S, D, D'Agostino RB, Lee DS, Kannel WB, Benjamin EJ, Vasan
Fumihiko M, Toshio N. Assessment of diastolic function in RS. Left ventricular hypertrophy patterns and incidence of
elderly patients with aortic stenosis. Evaluation of flow heart failure with preserved versus reduced ejection fraction.
propagation velocity using color M-mode Doppler technique. Am J Cardiol. 2014;113(1):117-22.
Geriatric Gerontol Int. 2005; 5: 242-247.
23. Popescu BA, Popescu AC, Antonini-Canterin F, Rubin D,
8. Gerard AP, William GH. Diastolic heart failure. The New Cappelletti P, Piazza R, Ginghina C, Dimulescu D, Beladan
England J Medicine. 2004;351:1097-105. CC, Nicolosi GL. Prognostic role of left atrial volume in elderly
9. El Aouar LM, Meyerfreud D, Magalhães P, Rodrigues SL, patients with symptomatic stable chronic heart failure:
Baldo MP, Brasil Y, El Aouar SM, El Aouar NA, Mill JG, comparison with left ventricular diastolic dysfunction and B-
Campos Filho O. Relationship between left atrial volume and type natriuretic peptide. Echocardiography. 2007;24(10):1035-
diastolic dysfunction in 500 Brazilian patients. Arq Bras 43.
Cardiol. 2013;101(1):52-8. 24. Yamamoto K, Origasa H, Hori M; J-DHF Investigators. Effects
10. Zouein FA, de Castro Brás LE, da Costa DV, Lindsey ML, of carvedilol on heart failure with preserved ejection fraction:
Kurdi M, Booz GW. Heart failure with preserved ejection the Japanese Diastolic Heart Failure Study (J-DHF). Eur J
fraction: emerging drug strategies. Journal of cardiovascular Heart Fail. 2013;15(1):110-8.
pharmacology. 2013; 62(1): 13. 25. Lalande S, Johnson BD. Diastolic dysfunction: a link between
11. Komamura K. Similarities and Differences between the hypertension and heart failure. Drugs Today (Barc).
Pathogenesis and Pathophysiology of Diastolic and Systolic 2008;44(7):503-13.
Heart Failure. Cardiol Res Pract. 2013;2013:824135. 26. Russo C, Jin Z, Homma S, Rundek T, Elkind MS, Sacco RL,
12. Ancona R, Comenale Pinto S, Caso P, D'Andrea A, Di Salvo Di Tullio MR. Left atrial minimum volume and reservoir function
G, Arenga F, Coppola MG, Sellitto V, Macrino M, Calabrò R. as correlates of left ventricular diastolic function: impact of left
Left atrium by echocardiography in clinical practice: from ventricular systolic function. Heart. 2012;98(10):813-20.
conventional methods to new echocardiographic techniques. 27. Edelmann F, Wachter R, Schmidt AG, Kraigher-Krainer E,
ScientificWorldJournal. 2014;2014:451042. Colantonio C, Kamke W, Duvinage A, Stahrenberg R,
13. Fontes-Carvalho R, Leite-Moreira A. Heart failure with Durstewitz K, Löffler M, Düngen HD, Tschöpe C, Herrmann-
preserved ejection fraction: fighting misconceptions for a new Lingen C, Halle M, Hasenfuss G, Gelbrich G, Pieske B; Aldo-
approach. Arq Bras Cardiol. 2011;96(6):504-14. DHF Investigators. Effect of spironolactone on diastolic
function and exercise capacity in patients with heart failure
14. Asrar ul Haq M, Wong C, Mutha V, Anavekar N, Lim K, Barlis with preserved ejection fraction: the Aldo-DHF randomized
P, Hare DL. Therapeutic interventions for heart failure with controlled trial. JAMA. 2013;309(8):781-91.
preserved ejection fraction: A summary of current evidence.
World J Cardiol. 2014;6(2):67-76.
15. Soma J. Heart failure with preserved left ventricular ejection
fraction: concepts, misconceptions and future directions. Blood
Press. 2011;20(3):129-33.
16. Kumar A, Meyerrose G, Sood V, Roongsritong C. Diastolic
heart failure in the elderly and the potential role of aldosterone
antagonists. Drugs Aging. 2006;23(4):299-308.
17. Paulus WJ, Tschöpe C, Sanderson JE, Rusconi C,
Flachskampf FA, Rademakers FE, Marino P, Smiseth OA, De
Keulenaer G, Leite-Moreira AF, Borbély A, Edes I, Handoko
ML, Heymans S, Pezzali N, Pieske B, Dickstein K, Fraser AG,
Brutsaert DL. How to diagnose diastolic heart failure: a
consensus statement on the diagnosis of heart failure with
normal left ventricular ejection fraction by the Heart Failure and
Echocardiography Associations of the European Society of
Cardiology. Eur Heart J. 2007;28(20):2539-50.
_______________________________________________________________________________________________________________________________